American Headache Society Annual Meeting
Distinctions between chronic, episodic migraine should include health care burden
SAN DIEGO — Distinctions between burdens faced by those who experience different levels of chronic and episodic migraine should be drawn according to external health care-related factors rather than by symptoms alone, according to a poster.
Daytime psilocybin adversely affects REM sleep in those with migraine
SAN DIEGO — Patients with migraine who received daytime psilocybin experienced reduced REM sleep, with effects lasting beyond the day of administration, according to a poster at the American Headache Society Annual Scientific Meeting.
Novel, oral therapeutic for migraine well-tolerated in healthy adults
SAN DIEGO — A novel, oral therapeutic for treatment of migraine was safe and well-tolerated in single ascending doses in a cohort of healthy adults, according to a speaker at the American Headache Society Annual Scientific Meeting.
Migraine stigma often impacts multiple personal, professional relationships
SAN DIEGO — The stigma that accompanies migraine is universal and often affects more than one personal or professional relationship, according to a speaker at the American Headache Society Annual Scientific Meeting.
Spontaneous intracranial hypotension significantly affects quality of life
SAN DIEGO – Spontaneous intracranial hypotension led to significant physical, mental and quality of life impact for a cohort of those with the condition, according to a speaker at the American Headache Society Annual Scientific Meeting.
Nutrient intake lower on days with nausea or vomiting in episodic migraine
SAN DIEGO —Individuals with episodic migraine had lower nutrient intake on days with nausea or vomiting compared with days without nausea, according to a poster from the American Headache Society Annual Scientific Meeting.
Combination of vaporized THC, CBD most effective at 2 hours for acute migraine
SAN DIEGO — A vaporized combination of THC and CBD was the most efficacious of four cannabis choices for acute moderate to severe migraine at 2 hours, according to an expert at the American Headache Society Annual Scientific Meeting.
AI-based models accurately predict, show promise for expansion in headache
SAN DIEGO — AI-based models are currently best utilized as a predictor of headache, but show promise for expansion into the health care continuum, according to a speaker at the American Headache Society Annual Scientific Meeting.
Concurrent atogepant, ubrogepant safe, well-tolerated for migraine at 12 weeks
SAN DIEGO — Concurrent use of atogepant for preventive treatment of episodic migraine and ubrogepant for acute migraine treatment was safe and well-tolerated at 12 weeks, according to a study.